Related News

Pictured: Jedd Wolchok and James Allison
The New Yorker Features Immune Therapy Work of Memorial Sloan-Kettering Researchers

In an article describing the history and promise of immunotherapy for cancer treatment, the magazine highlights the groundbreaking work of James Allison, Chair of the Sloan-Kettering Institute’s Immunology Program, and medical oncologist and immunologist Jedd Wolchok.

April 20, 2012
Pictured: Jedd Wolchok
Rare Medical Phenomenon: Melanoma Patient’s Tumors Disappear throughout the Body after Radiation of One Tumor

Findings from a multidisciplinary research team led by Memorial Sloan-Kettering medical oncologist and immunologist Jedd Wolchok could help shed light on the immune system’s role in fighting cancer.

March 8, 2012
Pictured: David Solit
Study Reveals How Some Skin Tumors May Evade New Therapy

Research led by investigators at Memorial Sloan-Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug vemurafenib.

March 1, 2012
Pictured: Memorial Sloan-Kettering logo
Memorial Sloan-Kettering Made Major Contributions to Cancer Advances in 2011

Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan-Kettering investigators.

February 6, 2012
Memorial Sloan-Kettering Researchers Appointed to Stand Up To Cancer Melanoma “Dream Team”

Five Memorial Sloan-Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.

December 14, 2011
Paul Chapman
New Targeted Therapy for Advanced Melanoma Associated with 80 Percent Response Rate

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan-Kettering Cancer Center and colleagues at other cancer centers have published their findings in the August 26 edition of the New England Journal of Medicine.

August 25, 2010
Novel Genetic Mutation that Causes the Most Common form of Eye Cancer Discovered

An international, multi-center study has revealed the discovery of a novel oncogene that is associated with uveal melanoma, the most common form of eye cancer. Researchers have isolated an oncogene called GNA11 and have found that it is present in more than 40 percent of tumor samples taken from patients with uveal melanoma.

November 17, 2010
Pictured: Jedd Wolchok & Paul Chapman
Memorial Sloan-Kettering Physician-Scientists Present Significant Clinical Cancer Research Advances at ASCO Annual Meeting

In an extraordinary demonstration of excellence, five Memorial Sloan-Kettering physician-scientists were selected to participate in the press program at the 2011 American Society of Clinical Oncology annual meeting, held June 3-7 in Chicago.

July 1, 2011
James Allison
Immunotherapy Drug Receives FDA Approval for Advanced Melanoma

The US Food and Drug Administration announced in late March that the drug ipilimumab (Yervoy™) had been approved for the treatment of patients with metastatic melanoma.

July 1, 2011
Paul Chapman
New Targeted Therapy Shows Promise for Advanced Melanoma

A multicenter study led by Memorial Sloan-Kettering Cancer Center investigators concluded that treatment with a new targeted therapy called PLX4032 resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma.

January 1, 2011